Evidence Library

China in pharmaceutical supply chains

The selected public sources describe industry supply chains. Their scope is separate from the facilities or services available for an individual quotation.

Companies, institutions and data are cited as public industry context. These references do not imply partnership, endorsement, certification or a commercial relationship with our company.

What the source covers

The selected public sources describe industry supply chains. Their scope is separate from the facilities or services available for an individual quotation.

Keep the scope clear

These independent sources do not establish a partnership with BLOPEP, certification of our products or approval of a particular batch. Follow the primary document for details and limitations.

Sources and verification scope

Reported trade data · S05

Brazil pharmaceutical imports by partner, HS 30, 2025 ↗

WITS / UN Comtrade

Source details (original language)
Scope
Brazilian imports of pharmaceutical products, HS chapter 30
Document section
Reporter Brazil, partner China; trade value 1000 USD
Limitations
Not peptide-only, not all APIs, and not Bolang sales.
Claim verification date
2026-09-09
Reported trade data · S06

Pharmaceutical imports from China, HS 30, 2025 ↗

WITS / UN Comtrade

Source details (original language)
Scope
Reported pharmaceutical imports from China, HS chapter 30
Document section
United States and European Union rows; trade value 1000 USD
Limitations
Do not add EU aggregate to member countries. Not peptide-only trade.
Claim verification date
2026-09-09
Corporate disclosure · S07

Eli Lilly and Company Form 10-K, fiscal year 2025 ↗

SEC · filing by Eli Lilly and Company

Source details (original language)
Scope
Lilly reports reliance on China-based suppliers for portions of its supply chain
Document section
Manufacturing and supply, p. 21; third-party supply chain risk factors
Limitations
Does not identify Bolang, peptide purchases from Bolang, partnership, endorsement or certification.
Claim verification date
2026-09-09
Corporate disclosure · S08

WuXi AppTec expands global manufacturing capacity ↗

WuXi AppTec

Source details (original language)
Scope
Corporate statement: >100,000 L at end of 2025; expansion toward 130,000 L
Document section
SPPS reactor volume paragraph
Limitations
WuXi AppTec capacity only; target is not installed capacity. Not WuXi Biologics or Bolang.
Claim verification date
2026-09-09
Corporate disclosure · S11

Notícias: cooperação e presença global ↗

Chemitex

Source details (original language)
Scope
Chemitex reports cooperation with Zhejiang Jiuzhou
Document section
Cooperation announcement and Presença Global em 2025
Limitations
Self-reported cooperation, not transaction-level customs evidence. Geographic wording was not repeated.
Claim verification date
2026-09-09

Related reading

Companies in public sources · Industry & Market

Chemitex

Company documents and their place in the pharmaceutical supply chain.

Read details →
Companies in public sources · Industry & Market

WuXi AppTec

Company documents and their place in the pharmaceutical supply chain.

Read details →